THRX

GlaxoSmithKline’s COPD drug Anoro receives European green light

[Reuters] – Anoro, a combination drug for chronic obstructive pulmonary disease (COPD) developed by GlaxoSmithKline and Theravance, has received the green light from European regulators, the companies said on Thursday. It is expected to generate sales of moreView todays social media effects on THRXView the latest stocks trending across Twitter. Click to view dashboardSee who Theravance is hiring next, click […]

Anoro(R) (umeclidinium / vilanterol) Receives Positive Opinion From the CHMP in Europe for the Treatment of COPD

[Marketwired] – GlaxoSmithKline plc and Theravance, Inc. today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation … moreView todays social media effects on THRXView the latest stocks trending across Twitter. Click to view dashboardSee who Theravance is hiring next, click here to view […]

GSK and Theravance Announce Regulatory Submission for ANOROâ„¢ ELLIPTAâ„¢ (UMEC/VI) in Japan

[at noodls] – LONDON and SOUTH SAN FRANCISCO, CA–(Marketwired – Apr 22, 2013) – GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the submission of a regulatory application to the Japanese … moreView todays social media effects on THRXView the latest stocks trending across Twitter. Click to view dashboardSee who Theravance is hiring next, click here to view […]

Theravance to Webcast 2013 Annual Meeting of Stockholders on April 24, 2013

[at noodls] – SOUTH SAN FRANCISCO, CA — (Marketwired) — 04/18/13 — Theravance, Inc. (NASDAQ: THRX) announced today that it will webcast its 2013 Annual Meeting of Stockholders at 1:00 p.m. Pacific Daylight Time on … moreView todays social media effects on THRXView the latest stocks trending across Twitter. Click to view dashboardSee who Theravance is hiring next, click here […]

GSK lung ‘wonder drug’ gets green light

moreView todays social media effects on THRXView the latest stocks trending across Twitter. Click to view dashboardSee who Theravance is hiring next, click here to view […]

FDA Advisory Committee Recommends Approval of BREO(TM) ELLIPTA(TM) for the Treatment of COPD

[at noodls] – LONDON and SOUTH SAN FRANCISCO, CA — (Marketwired) — 04/17/13 — GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Pulmonary-Allergy Drugs Advisory Committee … moreView todays social media effects on THRXView the latest stocks trending across Twitter. Click to view dashboardSee who Theravance is hiring next, click here to view […]

Trading in Theravance Common Stock Halted

[at noodls] – SOUTH SAN FRANCISCO, CA — (Marketwired) — 04/17/13 — Theravance, Inc. (NASDAQ: THRX) today announced that NASDAQ halted trading of Theravance common stock this morning, April 17, 2013. The Pulmonary-Allergy … moreView todays social media effects on THRXView the latest stocks trending across Twitter. Click to view dashboardSee who Theravance is hiring next, click here to view […]

Theravance to Report First Quarter 2013 Financial Results on April 25, 2013

[at noodls] – SOUTH SAN FRANCISCO, CA — (Marketwired) — 04/11/13 — Theravance, Inc. (NASDAQ: THRX) announced today that it will release financial results for the period ended March 31, 2013 after market close on … moreView todays social media effects on THRXView the latest stocks trending across Twitter. Click to view dashboardSee who Theravance is hiring next, click here […]

Clinigen and Theravance Announce Exclusive Commercialization Agreement in the EU for VIBATIV(R) (telavancin)

[at noodls] – BURTON-ON-TRENT, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA — (Marketwire) — 03/11/13 — Clinigen Group plc (LSE: CLIN) (AIM: CLIN) and Theravance, Inc. (NASDAQ: THRX) today announced that they have … moreView todays social media effects on THRXView the latest stocks trending across Twitter. Click to view dashboardSee who Theravance is hiring next, click here to view […]